Nexgel, Inc. (NXGLW) — SEC Filings
Nexgel, Inc. (NXGLW) — 38 SEC filings. Latest: 8-K (Dec 11, 2025). Includes 28 8-K, 4 10-Q, 3 DEF 14A.
View Nexgel, Inc. on SEC EDGAR
Overview
Nexgel, Inc. (NXGLW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 24, 2025: NexGel, Inc. filed an 8-K on November 24, 2025, reporting on events that occurred on November 21, 2025. The filing includes financial statements and exhibits, but the specific details of these events or financial figures are not provided in the excerpt.
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 37 neutral, 1 mixed. The dominant filing sentiment for Nexgel, Inc. is neutral.
Filing Type Overview
Nexgel, Inc. (NXGLW) has filed 28 8-K, 3 DEF 14A, 4 10-Q, 2 10-K, 1 10-K/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of NXGLW's 32 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Steven Glassman
- Joseph McGuire
- Adam Levy
- Robert L. Johnson
- Christopher J. Lytle
- David L. Smith
Industry Context
NexGel operates in the medical device sector, specifically focusing on advanced wound care and drug delivery technologies. The industry is characterized by significant research and development investment, stringent regulatory oversight from bodies like the FDA, and a competitive landscape with both large established players and smaller innovative companies. Trends include a growing demand for minimally invasive treatments, personalized medicine, and cost-effective solutions.
Top Tags
financial-reporting (7) · 8-K (5) · filing (5) · financials (5) · material-agreement (4) · 10-Q (4) · financial-condition (3) · results-of-operations (3) · 8-k (3) · equity-sale (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Current authorized common stock | 25,000,000 | Proposed to increase to 1,000,000,000 |
| Proposed authorized common stock | 1,000,000,000 | Represents a 3,900% increase from current levels |
| Current total authorized capital stock | 30,000,000 | Proposed to increase to 1,005,000,000 |
| Proposed total authorized capital stock | 1,005,000,000 | Includes 1,000,000,000 common and 5,000,000 preferred shares |
| Authorized preferred stock | 5,000,000 | Remains unchanged in the proposal |
| Shares of common stock issued and outstanding | 8,142,766 | As of the Record Date, October 20, 2025 |
| Par value per share of common stock | $0.001 | Remains unchanged |
| Date of Special Meeting | November 26, 2025 | Stockholders will vote on the Authorized Share Increase Proposal |
| Date Board unanimously approved proposal | October 16, 2025 | Subject to stockholder approval and Board implementation |
| Proxy voting deadline | 11:59 P.M. Eastern Time on November 25, 2025 | For internet or phone submissions |
| SEC File Number | 001-41173 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 26-4042544 | Company's tax identification number. |
| Reporting Period | Q1 2025 | First quarter of 2025 financial data |
| Fiscal Year End | 1231 | Company's fiscal year end date |
| Filing Date | 2025-03-27 | The date NexGel, Inc. submitted its 10-K to the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Nexgel, Inc. (NXGLW)?
Nexgel, Inc. has 38 recent SEC filings from Jan 2024 to Dec 2025, including 28 8-K, 4 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NXGLW filings?
Across 38 filings, the sentiment breakdown is: 37 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Nexgel, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Nexgel, Inc. (NXGLW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Nexgel, Inc.?
Key financial highlights from Nexgel, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NXGLW?
The investment thesis for NXGLW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Nexgel, Inc.?
Key executives identified across Nexgel, Inc.'s filings include Steven Glassman, Joseph McGuire, Adam Levy, Robert L. Johnson, Christopher J. Lytle and 1 others.
What are the main risk factors for Nexgel, Inc. stock?
Of NXGLW's 32 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Nexgel, Inc.?
Forward guidance and predictions for Nexgel, Inc. are extracted from SEC filings as they are enriched.